Mark is Co-founder/Editor of TechBuzz News. From Ogden, UT, Mark attended WSU, BYU, and Tufts. He has been involved in tech, media, publishing since the 80s.
Seek Labs (Salt Lake City, UT) has used its AI-powered discovery engine to identify genomic vulnerabilities in the measles virus—advancing a potential CRISPR-based antiviral platform as the U.S. faces its worst measles outbreak in decades.
Pattern (Lehi, UT) adds tech veterans Sue Taylor and Ann Mather to its Board of Directors, reinforcing strategic growth with AI tools unveiled at its Accelerate ecommerce conference.
Sworn (Provo, UT), an AI and public safety startup co-founded by crime tech veteran Sean Bair, has raised $1.2 million in seed funding to advance its biometric platform, which uses wearables and agency data to measure stress and improve the mental and physical health of police officers.
DASH (Germantown, WI) and S4i Systems (San Clemente, CA) have merged to form SMRTR (Cottonwood Heights, UT), a unified AP automation and compliance company offering cloud-based solutions to streamline operations for North American manufacturing and food & beverage businesses.
Tracer AI (Lehi, UT) launches Tracer Protect for ChatGPT, the first brand protection solution to proactively monitor and neutralize threats within AI chatbot outputs, leveraging its adaptive Flora platform to safeguard brand integrity at machine scale.
Utah sues Snap Inc., alleging it exploits children through addictive design, facilitates harm, and violates privacy laws, marking its fourth lawsuit against major social media firms. Snap responds.
Exploring critical infrastructure and legislative barriers limiting energy innovation, panelists at an energy strategy briefing discussed collaborative solutions and regulatory reform as essential to positioning Utah as a global leader in AI, data centers, and clean power deployment.
Nusano (West Valley City, UT) will supply isotopes iodine-125 and actinium-225 to Cellectar Biosciences (Florham Park, NJ) under a new agreement, supporting development of radiotherapeutics including CLR 125 for breast cancer and CLR 225 for pancreatic cancer.
